Novo's blockbuster diabetes drug Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as its popular obesity treatment Wegovy. Read more: https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/us-fda-approves-novo-nordisks-ozempic-to-cut-risk-of-diabetic-kidney-disease-progression/117669132